Chemotherapy compliance · patients with asymptomatic, incurable, metastatic colorectal cancer
1 finding from 1 review
Chemotherapy compliance · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery
Combination chemotherapy leads to lower chemotherapy compliance compared with single‐agent chemotherapy (high certainty).
1 finding from 1 review
Overall survival · patients with asymptomatic, incurable, metastatic colorectal cancer
Delayed chemotherapy showed no clear difference in overall survival compared with immediate chemotherapy (low certainty).
1 finding from 1 review
Nausea and vomiting · patients with asymptomatic, incurable, metastatic colorectal cancer
It is very uncertain whether delayed chemotherapy changes toxicity – nausea and vomiting compared with immediate chemotherapy (very low certainty).
1 finding from 1 review
Toxicity – stomatitis · patients with asymptomatic, incurable, metastatic colorectal cancer
It is very uncertain whether delayed chemotherapy changes toxicity – stomatitis compared with immediate chemotherapy (very low certainty).
1 finding from 1 review
Toxicity – diarrhoea · patients with asymptomatic, incurable, metastatic colorectal cancer
It is very uncertain whether delayed chemotherapy changes toxicity – diarrhoea compared with immediate chemotherapy (very low certainty).
1 finding from 1 review
Quality of life · patients with asymptomatic, incurable, metastatic colorectal cancer
1 finding from 1 review
Progression‐free survival · patients with asymptomatic, incurable, metastatic colorectal cancer
1 finding from 1 review
Overall survival (3 years) · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery
It is very uncertain whether combination chemotherapy changes overall survival (3 years) compared with single‐agent chemotherapy (very low certainty).
1 finding from 1 review
Disease-free survival · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery
It is very uncertain whether combination chemotherapy changes disease‐free survival (3 years) compared with single‐agent chemotherapy (very low certainty).
1 finding from 1 review
Complete response rate after preoperative chemoradiation (ypCR) · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery
Combination chemotherapy leads to higher complete response rate after preoperative chemoradiation (ypCR) compared with single‐agent chemotherapy (high certainty).
1 finding from 1 review
Toxicity ‐ early adverse events G3/4 · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery
Combination chemotherapy probably leads to higher toxicity ‐ early adverse events G3/4 compared with single‐agent chemotherapy (moderate certainty).
1 finding from 1 review
Metastases intra‐abdominal · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery
Combination chemotherapy showed no clear difference in metastases intra‐abdominal compared with single‐agent chemotherapy (moderate certainty).
1 finding from 1 review
Radiotherapy compliance · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery
Combination chemotherapy probably leads to lower radiotherapy compliance compared with single‐agent chemotherapy (moderate certainty).
1 finding from 1 review
Overall survival · people with metastatic CRC
Chemotherapy probably leads to lower overall survival compared with best supportive care (moderate certainty).
1 finding from 1 review
Progression‐free survival · people with metastatic CRC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tumour response · people with metastatic CRC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe adverse effects · people with metastatic CRC
Chemotherapy probably leads to higher severe adverse effects compared with best supportive care (moderate certainty).
1 finding from 1 review
Overall survival · people with metastatic CRC
Chemotherapy + bevacizumab leads to lower overall survival compared with chemotherapy (high certainty).
1 finding from 1 review
Progression‐free survival · people with metastatic CRC
Chemotherapy + bevacizumab leads to lower progression‐free survival compared with chemotherapy (high certainty).
1 finding from 1 review